Structure Therapeutics Inc. (GPCR) stock intrinsic value fair value estimate & owner earnings analysis

Structure Therapeutics is a clinical-stage drug developer with no approved product and no product revenue. Its lead candidate, aleniglipron (GSBR-1290), is an oral small-molecule GLP-1 receptor agonist for obesity, and the company is a US-listed Cayman Islands company (each ADS represents three ordinary shares) with headquarters in South San Francisco and a research and development office in Shanghai, China. It has five early-stage candidates in total. In its latest annual report it says it plans to start a Phase 3 registrational program for aleniglipron in the second half of 2026, after an End-of-Phase 2 meeting with the FDA. It also says it has manufacturing capacity of 6,000 tons a year for the drug. What we can and cannot credit. The company has never earned an operating profit. Owner earnings (operating cash flow less working-capital swings, stock compensation and capital spending) were about minus $97 million in 2023, minus $141 million in 2024 and minus $169 million in 2025, or roughly minus $2.64, minus $2.68 and minus $2.86 per ADS. The 2025 figure already includes a one-time $100 million upfront payment from Genentech and Roche for a non-exclusive patent license (cash received in January 2026); without it, 2025 would have been about minus $269 million. Because there is no earnings stream, we value the company as its cash less the spending needed to keep going, and we credit nothing for a future approval. Approval of an obesity drug would depend on Phase 3 trials that have not started, competing oral and injectable GLP-1 products from much larger companies, and regulatory outcomes, so we cannot point to anything secured that turns aleniglipron into earnings. We also credit nothing for the low-single-digit royalties from the Genentech license, which pay only if licensed products are sold, or for up to $90 million of contingent milestones under the August 2025 sale of early-stage non-obesity assets to Exelixis (in the base case), because neither is contractually locked in. Balance sheet. At June 30, 2026 the company held $272.6 million of cash and $1,070.0 million of short-term investments, about $1,342.7 million in total, and it has no borrowings. That works out to roughly $18.48 per ADS on about 218 million diluted ordinary shares (72.7 million ADS-equivalents, including pre-funded warrants). Operating leases run through operating cash flow and are not subtracted. Because there is no debt, nothing needs to be repaid ahead of shareholders, and none of the cases has a debt problem. The shares are worth the cash left after the company funds its programs. Base case: about $12.17 per ADS. The business is worth nothing on evidenced drivers, it owes nothing, and the difference is the cash. In the first half of 2026 cash from operations was minus $104.9 million even after collecting the $100 million Genentech payment, so the underlying burn was about $205 million for the six months, or roughly $410 million a year, with research spending doubling to $100 million in the second quarter as programs expand. We charge one year of that burn plus about $48 million of stock compensation (annualising the first-half 2026 charge of $24.3 million), a total of about $458 million, against the $1,342.7 million of cash. That leaves about $884 million. We stop the charge after one year because further spending is discretionary and depends on trial results we cannot yet know, and we credit no value from it either. Bear case: about $0.54 per ADS. The company states that its cash will fund operations and the Phase 3 program through the end of 2028. Assume it spends on that plan at that rate (about $1.2 billion from mid-2026), the program produces no valuable result, and it then incurs about $50 million of wind-down costs and a year of stock compensation. About $39 million, or roughly $0.54 per ADS, remains. The company's own risk factors say it will need substantial additional capital and that it cannot guarantee FDA alignment on the Phase 3 dose rationale or the size of the safety database. Bull case: about $13.41 per ADS. The same one-year burn applies, and the Exelixis milestones ($90 million) are received in full. We cannot point to anything else the company has secured, so the upside we can credit is small. Investors who hold the shares at prices well above the cash left after spending are paying for aleniglipron succeeding in Phase 3 and reaching the market. We treat that outcome as possible but cannot credit it, and it is the main way this valuation could be wrong on the upside. What would make this wrong. On the upside, a successful, FDA-aligned Phase 3 program or a large partnership for aleniglipron would create value that we do not credit. On the downside, Phase 3 costs could exceed the company's estimate, which excludes pre-commercialization costs such as commercial manufacturing, or new share issuance could dilute holders. We could not reconcile the exact current ordinary share count from the annual report alone, so we used the second-quarter 2026 diluted weighted average. Margin-of-safety price. The margin-of-safety price is $6.00 per ADS, about half the cash-based base value, keeping a large margin of safety because the company burns hundreds of millions a year, has no earnings, and its cash will be largely consumed by 2028 on its own estimate. It applies only once the FDA has aligned on the Phase 3 design and the program is fully funded from existing cash.